Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects

Pharmacotherapy

Volumn 28, Issue 7, 2008, Pages 863-874

  Cao, Ying Jun ^a   Smith, Patrick F ^b   Wire, Mary Beth ^c   Lou, Yu ^c   Lancaster, Charles T ^c   Causon, Roger C ^d   Bigelow, George E ^a   Martinez, Elizabeth ^a   Fuchs, Edward J ^a   Radebaugh, Christine ^a   McCabe, Sarah ^b   Hendrix, Craig W ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amprenavir; Fosamprenavir; Methadone; Pharmacodynamics; Pharmacokinetics; Ritonavir

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FOSAMPRENAVIR PLUS RITONAVIR; GAMMA GLUTAMYLTRANSFERASE; METHADONE; PARACETAMOL; RITONAVIR;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG SAFETY; DYSPEPSIA; ECG ABNORMALITY; ENANTIOMER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART RATE; HUMAN; MALE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; OPEN STUDY; PR PROLONGATION; QT PROLONGATION; RHINOPHARYNGITIS; SIDE EFFECT; SINUS BRADYCARDIA; STEADY STATE; SYSTOLIC BLOOD PRESSURE; VOMITING; YAWNING;

ADULT; ANTI-HIV AGENTS; CARBAMATES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHADONE; NARCOTICS; PHOSPHORIC ACID ESTERS; PRODRUGS; RITONAVIR; STEREOISOMERISM; SULFONAMIDES;

EID: 45749129426     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.7.863     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in the United States and dependent areas, 2005 (revised June 2007). Available from http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ 2005report/default.htm. Accessed October 4, 2007.
2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. October 10, 2006. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed October 04, 2007.
3. Kristensen K, Blemmer T, Angelo HR, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther DrugMonit 1996;18:221-7.
4. 1-acid glycoprotein. Clin Pharmacol Ther 1990;47:338-46.
5. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004;16:36-44.
6. Kharasch, ED, Hoffer, C, Whittington, D, Sheffels, P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69.
7. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007;321:389-99.
8. Wood R, Arasteh K, Stellbrink HJ, et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004;48:116-23.
9. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:22-32.
10. Gathe JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18:1529-37.
11. Elston RC, Yates P, Tisdale M, Richards N, White S, DeJesus E. GW433908 (908)/ritonavir (r): 48-week results in PI-experienced subjects - a retrospective analysis of virological response based on baseline genotype and phenotype. Presented at the 15th international AIDS conference, Bangkok, Thailand, July 11-16, 2004.
12. Livington DJ, Pazhanisamy S, Porter DJ, Partaledis JA, Tung RD, Painter GR. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis 1995;172:1238-45.
13. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87:803-7.
14. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy 2000;20:93-4.
15. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. J Acquir Immune Defic Syndr 2001;27:153-60.
16. Sabo JP, Macha S, Oksala C, et al. Stereoselective pharmacokinetics (PK) of methadone after coadministration with steady-state tipranavir/ritonavir 500/200 mg bid (TPV/r) in healthy volunteers. Presented at the 7th international workshop on clinical pharmacology of HIV therapy, Lisbon, Portugal, April 20-22, 2006.
17. Hsyu P-H, Lillibridge J, Daniels E, Kerr BM. Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. Biopharm Drug Dispos 2006;27:61-8.
18. Hendrix CW, Wakeford J, Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 2004;24:1110-21.
19. Abbott Laboratories. Norvir (ritonavir) product information. North Chicago, IL; 2006.
20. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003;37:476-82.
21. Regulatory Compliance Center. ACTG adverse event grading tables. Division of AIDS table for grading the severity of adult and pediatric adverse events, Version 1.0, December 2004. Available from http://rcc.tech-res.com/ DAIDS%20RCC%20Forms/ToxicityTables_DAIDS_AE_GradingTable_FinalDec2004.pdf. Accessed May 31, 2007.
22. Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999;65:685-94.
23. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995;119:268-76.
24. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl) 2002;161:202-12.
25. McLeod DR, Griffiths RR, Bigelow GE, Yingling J. An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 1982;14:463-6.
26. GlaxoSmithKline. Data on file. Research Triangle Park, NC; 2005.
27. Shelton MJ, Cloen D, DiFrancesco R, et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol 2004;44:293-304.
28. Jamois C, Riek A, Patel A, Smith PF, Morrison R, Schmitt C. Effect of boosted saquinavir on the pharmacokinetics and pharmacodynamics of racemic methadone in opiate-dependent patients on stable methadone maintenance therapy. Presented at the 8th international congress on drug therapy in HIV infection, Glasgow, United Kingdom, November 12-16, 2006.
29. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002;34:1143-5.
30. Sekar V, El Malt M, De Paepe E, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and methadone. Presented at the 8th international congress on drug therapy in HIV infection, Glasgow, United Kingdom, November 12-16, 2006.
31. Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005;19:1635-41.
32. Cantinela L, McCrea J, Blazes D, et al. Lack of a pharmacokinetic interaction between indinavir and methadone [abstract]. Clin Pharmacol Ther 1999;65:135.
33. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987;41:392-401.